@Butydoc, I was afraid someone would ask this, should have kept better notes!
Here are some of the articles I looked at, most from cancer journals, but the parts about the mechanisms of the antivirals are not cancer-specific. (Notice they're all about valcyte, I'm figuring the mechanism might be the same for all the antiherpes AVs, but not sure).
I accessed the articles via my University so not sure if they are available freely, happy to supply copies if you would like.
Would love your thoughts on all this as a professional!
Israel, B. F., & Kenney, S. C. (2003). Virally targeted therapies for EBV-associated malignancies. Oncogene, 22(33), 5122-5130. (review article)
The relevant bit: "Tumor cells containing the lytic (but not latent) type of EBV infection express virally encoded kinases (BGLF4 and the viral thymidine kinase) that induce phosphorylation of the prodrug, GCV, converting it to its active cytotoxic form (Moore et al., 2001). Phosphorylated GCV inhibits not only the virally encoded DNA polymerase, but also inhibits the host cell DNA polymerase and is thus cytotoxic (Tiberghien, 1994; Conners, 1995). Furthermore, phosphorylated GCV can be transferred into nearby cells, thus inducing 'bystander' killing (Freeman et al., 1993; Chen et al., 1995; Conners, 1995).
Feng, W. H., Hong, G., Delecluse, H. J., & Kenney, S. C. (2004). Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. Journal of virology, 78(4), 1893-1902.
The relevant bit: "EBV manifests two distinct phases in its life cycle: latency and lytic replication. During latency, EBV expresses a limited number of viral genes, which are involved in tasks such as stimulating cell proliferation, inhibiting apoptosis, blocking viral lytic replication, and assuring accurate and equal partitioning of the episomal viral genome to daughter cells (31, 43). However, during the lytic replication phase of the EBV life cycle, many more viral genes are expressed which encode proteins involved in viral DNA replication and viral particle synthesis. In addition, during the lytic form of infection, two virally encoded kinases, the EBV thymidine kinase (EBV-TK) and the BGLF4 gene product, which phosphorylate the prodrug GCV and convert it into its active cytotoxic form (11, 33, 37, 41, 53), are expressed. Phosphorylated GCV inhibits not only the virally encoded DNA polymerase but also the cellular DNA polymerase, leading to premature termination of the nascent DNA and cell death (14, 23, 34). In addition, phosphorylated GCV can be transferred to adjacent cells, thus inducing “bystander” killing (23). Lytic EBV infection also confers sensitivity to the cytotoxic effects of zidovudine (AZT), possibly by inducing AZT phosphorylation (10, 28, 41, 52). However, GCV and AZT are not generally effective for treating EBV-positive tumors because most tumor cells are infected with the latent form of EBV and therefore do not express the kinases which activate these drugs."
Young, L. S., & Rickinson, A. B. (2004). Epstein–Barr virus: 40 years on. Nature Reviews Cancer, 4(10), 757-768.
The relevant bit: “Other approaches are based on the induction of the EBV lytic cycle, either by pharmacological agents or by delivery of EBV immediate-early genes, thereby inducing virus-encoded kinases (EBV thymidine kinase and BGLF4, a protein kinase) that phosphorylate the nucleoside analogue gancyclovir to produce its active cytotoxic form”.